, ne permettant donc pas un recul suffisant pour permettre d'affirmer avec certitude l'absence d'évolution du MGUS entre les deux groupes. Par ailleurs, l'effectif de certaines sous-populations était malheureusement trop faible pour permettre d'observer une différence entre les deux groupes. C'est notamment le cas pour les patients splénectomisés qui n'étaient que 2 dans le groupe des patients PTI/MGUS. L'inclusion de nouveaux patients, ainsi que l'extension de leur durée de suivi, auraient permis d'augmenter la puissance de cette étude et auraient probablement apporté plus de sensibilité à l'observation de différences entre les deux groupes. C'est actuellement l'objectif d'une étude nationale menée par le Dr Mahévas et G. Bonnard (Hôpital Mondor)

S. Deane, S. S. Teuber, and M. E. Gershwin, The geoepidemiology of immune thrombocytopenic purpura, Autoimmun Rev, vol.9, pp.342-349, 2010.

G. Moulis, Epidemiology of incident immune thrombocytopenia: a nationwide populationbased study in France, Blood, vol.124, pp.3308-3315, 2014.

G. Moulis, M. Lapeyre-mestre, D. Adoue, and L. Sailler,

, Rev Med Interne, vol.38, pp.444-449, 2017.

W. M. Schoonen, Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database, Br. J. Haematol, vol.145, pp.235-244, 2009.

A. J. Neylon, Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients, Br. J. Haematol, vol.122, pp.966-974, 2003.

G. Moulis, L. Sailler, D. Adoue, and M. Lapeyre-mestre, Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies, Therapie, vol.69, pp.437-448, 2014.

S. Audia, B. Lorcerie, B. Godeau, and B. Bonnotte, Physiopathologie du purpura thrombopénique immunologique, La Revue de Médecine Interne, vol.32, pp.350-357, 2011.

S. Nomura, Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura, Blood, vol.91, pp.3616-3622, 1998.

M. H. Maia, Predisposition to idiopathic thrombocytopenic purpura maps close to the major histocompatibility complex class I chain-related gene A, Hum. Immunol, vol.70, pp.179-183, 2009.

V. Castro, G. B. Oliveira, A. F. Origa, J. M. Annichino-bizzacchi, and V. R. Arruda, The human platelet alloantigen 5 polymorphism as a risk for the development of acute idiopathic thrombocytopenia purpura, Thromb. Haemost, vol.84, pp.360-361, 2000.

H. Thude, E. Gatzka, O. Anders, and D. Barz, Allele frequencies of human platelet antigen 1, 2, 3, and 5 systems in patients with chronic refractory autoimmune thrombocytopenia and in normal persons, Vox Sang, vol.77, pp.149-153, 1999.

C. B. Foster, Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study, Br. J. Haematol, vol.113, pp.596-599, 2001.

F. Emmerich, High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura, Br. J. Haematol, vol.136, pp.309-314, 2007.

H. Zhao, Reduced MIR130A is involved in primary immune thrombocytopenia via targeting TGFB1 and IL18, Br. J. Haematol, vol.166, pp.767-773, 2014.

R. Stasi, Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review, Blood, vol.113, pp.1231-1240, 2009.

T. Takahashi, Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura, Br. J. Haematol, vol.124, pp.91-96, 2004.

A. Bettaieb, E. Oksenhendler, N. Duedari, and P. Bierling, Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura, Clin. Exp. Immunol, vol.103, pp.19-23, 1996.

W. Zhang, M. A. Nardi, W. Borkowsky, Z. Li, and S. Karpatkin, Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia, Blood, vol.113, pp.4086-4093, 2009.

H. Ogawara, High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura, Eur. J. Haematol, vol.71, pp.283-288, 2003.

T. Wang, Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura, Haematologica, vol.90, pp.914-923, 2005.

F. P. Panitsas, Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response, Blood, vol.103, pp.2645-2647, 2004.

R. Stasi, Response to B-cell depleting therapy with rituximab reverts the abnormalities of Tcell subsets in patients with idiopathic thrombocytopenic purpura, Blood, vol.110, pp.2924-2930, 2007.

S. Audia, M. Mahévas, M. Samson, B. Godeau, and B. Bonnotte, Pathogenesis of immune thrombocytopenia, Autoimmun Rev, vol.16, pp.620-632, 2017.
URL : https://hal.archives-ouvertes.fr/tel-00687984

J. Garcia-suarez, Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3-natural killer cells subset, Blood, vol.82, pp.1538-1545, 1993.

B. Liu, Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura, Eur. J. Haematol, vol.78, pp.139-143, 2007.

R. Mcmillan, L. Wang, A. Tomer, J. Nichol, and J. Pistillo, Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP, Blood, vol.103, pp.1364-1369, 2004.

M. Kuwana, Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia, Arthritis Rheum, vol.46, pp.2148-2159, 2002.

S. Kosugi, Circulating thrombopoietin level in chronic immune thrombocytopenic purpura, Br. J. Haematol, vol.93, pp.704-706, 1996.

F. Rodeghiero, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, vol.113, pp.2386-2393, 2009.

R. Stasi, S. Amadori, J. Osborn, A. C. Newland, and D. Provan, Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia, PLoS Med, vol.3, p.24, 2006.

B. J. Bain, Ethnic and sex differences in the total and differential white cell count and platelet count, J. Clin. Pathol, vol.49, pp.664-666, 1996.

, Protocole national de diagnostic et de soins (PNDS) du purpura thrombopénique immunologique de l'enfant et de l'adulte, 2017.

L. Grimaldi-bensouda, Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome, Haematologica, vol.101, pp.1039-1045, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02042400

E. Weber, Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study, Rev Med Interne, vol.38, pp.167-175, 2017.

M. Khellaf, Helicobacter pylori et Purpura thrombopénique immunologique (PTI) : résultats d'une enquête prospective monocentrique sur la prévalence de l'infection et l'effet de l'éradication sur l'évolution du PTI. La Revue de Médecine Interne, vol.30, pp.350-351, 2009.

M. D. Beardsley, .. D. Ph, D. S. Ertem, and M. D. Mehmet, Platelet Autoantibodies in Immune Thrombocytopenic Purpura, Transfusion Science, vol.19, pp.237-244, 1998.

V. Kiefel, S. Santoso, M. Weisheit, and C. Müeller-eckhardt, Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies, Blood, vol.70, pp.1722-1726, 1987.

G. Moulis, Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort, Am. J. Hematol, vol.92, pp.493-500, 2017.

L. Grimaldi, Caractéristiques et devenir du purpura thrombopénique immunologique nouvellement diagnostiqué chez l'adulte : résultats d'une étude de cohorte observationnelle et prospective. La Revue de, Médecine Interne, vol.36, pp.97-98, 2015.

L. Damian, Thrombopénie immunologique primaire de l'adulte : facteurs prédictifs d'évolution vers la chronicité, 2018.

M. Nørgaard, Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study, Blood, vol.117, pp.3514-3520, 2011.

C. Neunert, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood, vol.117, pp.4190-4207, 2011.

R. Stasi and D. Provan, Management of immune thrombocytopenic purpura in adults, Mayo Clin. Proc, vol.79, pp.504-522, 2004.

G. Noël-cozon and . Jacques, Immunoglobulines G humaines polyvalentes : Utilisation thérapeutique en 2016. Revue Francophone des Laboratoires, pp.59-64, 2016.

G. Immunoglobulines and . Polyvalentes, Utilisation thérapeutique en 2016. Revue Francophone des Laboratoires, pp.59-64, 2016.

G. E. Pamuk, Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy, Ann. Hematol, vol.81, pp.436-440, 2002.

B. Godeau, Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w, Br. J. Haematol, vol.107, pp.716-719, 1999.

C. Arnal, Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases, J. Rheumatol, vol.29, pp.75-83, 2002.

M. Khellaf, Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies, Am. J. Hematol, vol.89, pp.194-198, 2014.

D. M. Arnold, Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura, Ann. Intern. Med, vol.146, pp.25-33, 2007.

N. Cooper, State of the art -how I manage immune thrombocytopenia, Br. J. Haematol, vol.177, pp.39-54, 2017.

M. Medeot, Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results, Eur. J. Haematol, vol.81, pp.165-169, 2008.

S. Deshayes, Efficacité à long terme du rituximab chez 248 patients adultes atteints de purpura thrombopénique immunologique : résultats avec plus de 5 ans de recul du registre prospectif national PTI-RITUX, La Revue de Médecine Interne, vol.39, p.62, 2018.

M. Mahévas, Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia, Am. J. Hematol, vol.88, pp.858-861, 2013.

J. B. Bussel, Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial, Lancet, vol.373, pp.641-648, 2009.

D. J. Kuter, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial, Lancet, vol.371, pp.395-403, 2008.

J. B. Bussel, Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP, Blood, vol.113, pp.2161-2171, 2009.

M. Mingot-castellano, C. Grande-garcía, D. Valcárcel-ferreiras, C. Conill-cortés, and L. De-olivar-oliver, Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain. Case Rep Hematol, p.4109605, 2017.

A. Cuker, Toxicities of the thrombopoietic growth factors, Semin. Hematol, vol.47, pp.289-298, 2010.

A. D. Schreiber, P. Chien, A. Tomaski, and D. B. Cines, Effect of danazol in immune thrombocytopenic purpura, N. Engl. J. Med, vol.316, pp.503-508, 1987.

M. Uchiyama, Induction of regulatory CD4 + cells and prolongation of survival of fully allogeneic murine cardiac grafts by danazol, Transplant. Proc, vol.44, pp.1067-1069, 2012.

S. Daou, Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center, Eur. J. Intern. Med, vol.19, pp.447-451, 2008.

, Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results, 2019.

J. M. Durand, P. Lefèvre, P. Hovette, M. Mongin, and J. Soubeyrand, Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients, Br. J. Haematol, vol.78, pp.459-460, 1991.

C. Estève, Efficacité et tolérance de la dapsone en traitement de seconde ligne de la thrombopénie immunologique de l'adulte. La Revue de, Médecine Interne, vol.37, pp.138-139, 2016.

B. Godeau, E. Oksenhendler, and P. Bierling, Dapsone for autoimmune thrombocytopenic purpura, Am. J. Hematol, vol.44, pp.70-72, 1993.

E. Weber, Évaluation des immunosuppresseurs dans le PTI réfractaire par revue systématique et méta-analyse de 37 études, La Revue de Médecine Interne, vol.36, p.38, 2015.

J. Stirnemann, Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients, Eur. J. Haematol, vol.96, pp.269-275, 2016.

E. Crickx, Utilisation des agonistes du récepteur à la thrombopoïétine (ARTPO) en association avec un immunosuppresseur au cours du PTI de l'adulte multiréfractaire. Etude rétrospective multicentrique du centre de référence des cytopénies auto-immunes de l'adulte, La Revue de Médecine Interne, vol.39, pp.38-39, 2018.

M. Mahévas, Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia, Blood, vol.128, pp.1625-1630, 2016.

É. Cornet, Classification OMS 2017 des tumeurs plasmocytaires. Revue Francophone des Laboratoires, pp.34-40, 2019.

S. V. Rajkumar, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014.

T. Stojkovic, Neuropathie, gammapathie monoclonale et auto-anticorps : comment établir un lien ?, Revue Neurologique, vol.163, pp.45-53, 2007.

R. A. Kyle, A long-term study of prognosis in monoclonal gammopathy of undetermined significance, N. Engl. J. Med, vol.346, pp.564-569, 2002.

R. A. Kyle, Prevalence of monoclonal gammopathy of undetermined significance, N. Engl. J. Med, vol.354, pp.1362-1369, 2006.

O. Landgren, Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States, Blood, vol.107, pp.904-906, 2006.

O. Landgren, Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana, Mayo Clin. Proc, vol.82, pp.1468-1473, 2007.

O. Landgren, Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women, Blood, vol.116, pp.1056-1059, 2010.

O. Landgren, Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study, Blood, vol.113, pp.6386-6391, 2009.

C. M. Vachon, Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance, Blood, vol.114, pp.785-790, 2009.

C. Pawlyn and G. J. Morgan, Evolutionary biology of high-risk multiple myeloma, Nat. Rev. Cancer, vol.17, pp.543-556, 2017.

R. Fonseca, The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, vol.102, pp.2562-2567, 2003.

P. L. Bergsagel, Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, vol.106, pp.296-303, 2005.

A. Mikulasova, Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance, Eur. J. Haematol, vol.97, pp.568-575, 2016.

A. Rossi, Mutational landscape reflects the biological continuum of plasma cell dyscrasias, Blood Cancer J, vol.7, p.537, 2017.

B. A. Walker, Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma, Blood, vol.117, pp.553-562, 2011.

G. R. Ra and S. I. Heterogeneity, Novel Approaches for Resolving Genomic Architecture and Clonal Evolution

N. Van-nieuwenhuijzen, I. Spaan, R. Raymakers, and V. Peperzak, From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells, Cancer Res, vol.78, pp.2449-2456, 2018.

C. Emile, Électrophorèse des protéines sériques : principes généraux -vérification de méthodeinterprétation, Option/Bio, vol.24, pp.20-22, 2013.

, Chapitre 9 -Exploration des immunoglobulines, Méthodes en Immunologie, pp.167-178, 2014.

R. A. Kyle, Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance, N Engl J Med, vol.378, pp.241-249, 2018.

R. A. Kyle, Long-term follow-up of IgM monoclonal gammopathy of undetermined significance, Blood, vol.102, pp.3759-3764, 2003.

O. Decaux, Suivi évolutif des gammapathies monoclonales de signification indéterminée: Étude rétrospective de 190 patients, La Presse Médicale, vol.35, pp.1143-1150, 2006.

S. V. Rajkumar, Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance, Blood, vol.106, pp.812-817, 2005.

R. A. Kyle, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, vol.24, pp.1121-1127, 2010.

R. Bataille, The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy, Haematologica, vol.91, pp.1234-1240, 2006.

E. Pérez-persona, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells, Blood, vol.110, pp.2586-2592, 2007.

R. A. Kyle, Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later, Mayo Clin. Proc, vol.79, pp.859-866, 2004.

S. Y. Kristinsson, Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study, Haematologica, vol.94, pp.1714-1720, 2009.

K. C. Söderberg, Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden, 2019.

S. Rosthøj, Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: A prospective Nordic study of an unselected cohort, J. Pediatr, vol.143, pp.302-307, 2003.

Y. M. Ali, M. B. Urowitz, D. Ibanez, and D. D. Gladman, Monoclonal gammopathy in systemic lupus erythematosus, Lupus, vol.16, pp.426-429, 2007.

D. Rossi, Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance, Br. J. Haematol, vol.138, pp.249-252, 2007.

R. K. Wadhera and S. V. Rajkumar, Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review, Mayo Clin Proc, vol.85, pp.933-942, 2010.

L. A. Anderson, Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies, Int. J. Cancer, vol.125, pp.398-405, 2009.

E. Faller, Immune thrombocytopenia purpura associated with multiple myeloma, Ann. Hematol, vol.95, pp.1371-1372, 2016.

V. Gupta, U. M. Hegde, R. Parameswaran, and A. C. Newland, Multiple myeloma and immune thrombocytopenia, Clin Lab Haematol, vol.22, pp.239-242, 2000.

H. Yao, Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature, Int J Clin Exp Pathol, vol.8, pp.15429-15432, 2015.

K. Nakazaki, IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia, Int. J. Hematol, vol.92, pp.360-363, 2010.

N. Leung, Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant, Blood, vol.120, pp.4292-4295, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00945713

J. Lin, Renal monoclonal immunoglobulin deposition disease: the disease spectrum, J. Am. Soc. Nephrol, vol.12, pp.1482-1492, 2001.

S. H. Nasr, Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution, Clin J Am Soc Nephrol, vol.7, pp.231-239, 2012.

C. P. Venner, Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival, Blood, vol.119, pp.4387-4390, 2012.

S. T. Nagendran, C. Pawlyn, M. Brown, and L. Pelosini, Crystalline keratopathy associated with monoclonal gammopathy of undetermined significance, Br. J. Haematol, vol.159, p.258, 2012.

J. Grabska and C. A. Dasanu, Autoimmune phenomena in untreated and treated marginal zone lymphoma, Expert Opin Pharmacother, vol.12, pp.2369-2379, 2011.

C. M. Mcshane, Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review, Cancer Epidemiol. Biomarkers Prev, vol.23, pp.332-342, 2014.

E. K. Lindqvist, Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study, Blood, vol.118, pp.6284-6291, 2011.

A. Shimanovsky, A. J. Alvarez, S. Murali, and C. A. Dasanu, Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance, BBA Clinical, vol.6, pp.12-18, 2016.

S. V. Glavey and N. Leung, Monoclonal gammopathy: The good, the bad and the ugly, Blood Rev, vol.30, pp.223-231, 2016.

G. Carlizzi, Autoantibodies in patients with monoclonal gammopathies, Ann. N. Y. Acad. Sci, vol.1107, pp.206-211, 2007.

M. J. Stone, Human monoclonal macroglobulins with antibody activity, Semin. Oncol, vol.30, pp.318-324, 2003.

G. Diminno, A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder, J. Clin. Invest, vol.77, pp.157-164, 1986.